Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$50.76 USD

50.76
2,262,676

+4.37 (9.42%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $50.99 +0.23 (0.45%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected

by Zacks Equity Research

CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.76% and 93.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised

by Zacks Equity Research

Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.

Gilead Sciences (GILD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?

by Ekta Bagri

While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

by Zacks Equity Research

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 92.54% and 810.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Ahan Chakraborty

Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanghamitra Saha headshot

Best ETFs of Last Week

by Sanghamitra Saha

Wall Street offered a mixed performance last week.

CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $57.92, signifying a +0.61% move from its prior day's close.

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $57.19 in the latest trading session, marking a +1.69% move from the prior day.

Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.

What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?

by Zacks Equity Research

On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

Ekta Bagri headshot

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?

by Ekta Bagri

While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.

CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $55.56 in the latest trading session, marking a +0.96% move from the prior day.

Kinjel Shah headshot

Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?

by Kinjel Shah

While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $56.63 in the latest trading session, marking a +1.22% move from the prior day.

Is Most-Watched Stock CRISPR Therapeutics AG (CRSP) Worth Betting on Now?

by Zacks Equity Research

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reachead $59.60 at the closing of the latest trading day, reflecting a -1.6% change compared to its last close.

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

by Zacks Equity Research

Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $65.26, representing a +0.66% change from its previous close.

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.